
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing robust growth, particularly through its Auryon product line, which is expanding its customer base in both outpatient business locations and hospitals, thereby enhancing average selling prices (ASP). The company is also on track to improve its gross margin, which is currently at 52.5%, through ongoing manufacturing initiatives expected to be completed by January 2026, alongside a favorable revenue mix skewed towards higher Med-Tech revenues. Additionally, management is optimistic about sustained growth driven by acquiring new customers, increasing utilization in existing accounts, and effective pricing strategies in place.
Bears say
AngioDynamics faces significant challenges, including anticipated tariff headwinds of $4M-$6M, which could adversely affect its profitability. Additionally, the company's management has expressed concerns regarding increased raw material prices, potentially impacting inventory for the second half of 2026. Furthermore, while recent capital sales have boosted performance, the reliance on this segment raises questions about the sustainability of future disposable demand.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares